Brief: Calliditas Partner STADA Receives Positive CHMP Opinion Recommending Full Approval For Kinpeygo For Treatment Of Iga Nephropathy
30/05/2024 19:02
May 30 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS PARTNER STADA RECEIVES POSITIVE CHMP OPINION
RECOMMENDING FULL APPROVAL FOR KINPEYGO ® FOR TREATMENT OF IGA
NEPHROPATHY
* A FINAL DECISION BY EC ON GRANTING A MARKETING
AUTHORISATION IS
ANTICIPATED IN AUGUST 2024.
Source text for Eikon: ID:nWkrbg4W1b
Further company coverage: CALTX.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations